Outsourcing-Pharma: Targeting special patient populations with the help of AI

August 2, 2018

One of the biggest challenges of clinical trials is identifying the specific patient populations. This is a factor that has become even more critical with the rise of highly targeted oncology medicines. The solution: Artificial intelligence (AI) techniques which unify structured and unstructured clinical patient data for real-time accessibility.

To meet the demand of finding patients with highly specific mutational contexts of drug sensitivity for trial participation, TD2 turned to Deep 6 AI. Using a variety of AI and natural language processing (NLP) techniques, Deep 6 AI creates “patient graphs” from structured and unstructured data from every clinical event in a patient’s life and how those events relate.

For TD2, patients can be matched against clinical trial eligibility criteria in minutes, rather than the months it currently takes.

Hear from TD2 president and CEO, Stephen Gately and Deep 6 AI cofounder and CEO, Wout Brusselaers about the partnership and what the future holds for AI in drug development in Outsourcing-Pharma.

Optimizing Site Selection for Faster Patient Enrollment in Oncology Trials

Effective site selection is critical to the success of any clinical trial, especially in oncology, where patient recruitment can be particularly ...

Read more +

Choosing the Right DIO Mouse Model for Your Oncology Study

Diet-induced obesity (DIO) mouse models are integral to the exploration of obesity's role in cancer etiology, offering detailed insights into the ...

Read more +

Navigating the Complexities of Clinical Trial Start-Up

The Challenge: Overcoming Inefficiencies in Trial Start-Up The period between receiving the FDA’s “May Proceed” letter and activating trial sites for ...

Read more +

Get Started

Contact Us Today!

If you’re looking for an expert team to guide your trial with efficiency in mind, we can help. As the creators of the Dynamic Trial, TD2 provides start-to-finish support with trial strategy, design and execution for faster go-to-market potential.